Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 3Recruiting 3Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Breast Neoplasms 849Triple Negative Breast Neoplasms 136Ovarian Neoplasms 55Colorectal Neoplasms 49Carcinoma, Non-Small-Cell Lung 47Neoplasms 43Neoplasm Metastasis 43Prostatic Neoplasms 42Lung Neoplasms 38Melanoma 30Carcinoma, Intraductal, Noninfiltrating 29Uterine Cervical Neoplasms 27Pancreatic Neoplasms 25Colonic Neoplasms 25Stomach Neoplasms 23Squamous Cell Carcinoma of Head and Neck 23Endometrial Neoplasms 23Carcinoma, Renal Cell 23Breast Carcinoma In Situ 22Esophageal Neoplasms 17Urinary Bladder Neoplasms 16Motor Activity 16Inflammatory Breast Neoplasms 16Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 14Breast Cancer Female 13Brain Neoplasms 12Anatomic Stage I Breast Cancer AJCC v8 12Gastrointestinal Neoplasms 11

Interventions

tucatinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Fulvestrant 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Metastatic Breast Cancer × Breast × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Criterium, Inc.

Phase 1/2 Active not recruiting
40 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡